Tatiana Reitblat

Title: **Tatiana Reitblat: Innovator in Dry Eye Treatment**

Introduction

Tatiana Reitblat is an accomplished inventor based in Petach Tikva, Israel, known for her significant contribution to the treatment of dry eye conditions. Her innovative approach utilizes a specific agonist to alleviate symptoms that affect the quality of life for many individuals.

Latest Patents

Tatiana holds a patent for a groundbreaking method aimed at treating dry eye conditions. The patent describes a method that involves administering an effective amount of an adenosine receptor (AAR) agonist to ameliorate symptoms associated with this condition. The symptoms include foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, and excessive tearing. A notable component of her invention is the use of N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) as a preferred AAR agonist.

Career Highlights

Tatiana is currently affiliated with Can-Fite Biopharma Ltd., where she continues to develop innovative therapies for various medical conditions. Her expertise and dedication to research have positioned her as a key figure in pharmaceutical innovation, particularly in ophthalmology.

Collaborations

Throughout her career, Tatiana has collaborated with notable colleagues such as Pnina Fishman and Ilan Cohn. These partnerships have enhanced her research endeavors and contributed to the advancement of treatment options for patients suffering from dry eye conditions.

Conclusion

Tatiana Reitblat's work exemplifies the spirit of innovation in the medical field. Her patented method for treating dry eye conditions is a testament to her commitment to improving patient outcomes. As researchers and inventors like Tatiana continue to push the boundaries of medical science, the future looks promising for those affected by ocular discomfort.